First 4 patients staggered over 4 months, FDA mandate for safety.
The rest of the patients will take 4-8 months.
MD Anderson sees 40 AML patients every month but they want to choose the right patients.
The patient population we're treating are in the adverse group.
Of that group, after the first 2 months the remission rate is 45-60%. Of the 45-60%, 80% relapse.
If we can pump up that remission rate by 20-35% and deep remission from 15-20% to 40-50%, we should see overall survival increase 20-35% but it could be more.
Overall survival with this patient population is 30-40% after a year and 10-15% after 4 years.
We should have a good idea of efficacy within the first couple of months of the trials patient population being treated.
- Forums
- ASX - By Stock
- Chimeric: Media Thread
First 4 patients staggered over 4 months, FDA mandate for...
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.7¢ |
Change
-0.002(6.90%) |
Mkt cap ! $23.12M |
Open | High | Low | Value | Volume |
2.9¢ | 2.9¢ | 2.7¢ | $14.49K | 518.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 1378548 | 2.7¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.8¢ | 158093 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 1378548 | 0.027 |
6 | 812615 | 0.026 |
6 | 910000 | 0.025 |
10 | 1506666 | 0.024 |
9 | 2772007 | 0.023 |
Price($) | Vol. | No. |
---|---|---|
0.028 | 158093 | 2 |
0.029 | 25624 | 1 |
0.030 | 221388 | 3 |
0.031 | 451071 | 4 |
0.032 | 1550000 | 3 |
Last trade - 15.59pm 06/05/2024 (20 minute delay) ? |
|
|||||
Last
2.8¢ |
  |
Change
-0.002 ( 0.00 %) |
|||
Open | High | Low | Volume | ||
2.8¢ | 2.8¢ | 2.8¢ | 252061 | ||
Last updated 15.47pm 06/05/2024 ? |
Featured News
CHM (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
Previous Video
Next Video
SPONSORED BY The Market Online